natgillin/translations-raw huggingface dataset:
System according to any of the preceding claims 7 to 10, characterized in that the capsule handling means (21) comprises a slider (23) or tubular feeder for guiding the capsule in a capsule holder (24) movably placed underneath. 
Sustav u skladu s bilo kojim od prethodnih patentnih zahtjeva 7 do 10, naznačen time što sustav za manipuliranje kapsulom (21) sadrži kliznik (23) ili cjevasti posluživač za uvođenje kapsule u držač kapsule (24), koji je na pokretan način smješten odozdo.
A capsule for the preparation of a beverage from beverage ingredients contained therein, the capsule comprising: 
Kapsula za pripravu napitka iz sastojaka za napitak koji se nalaze u njoj, koja se sastoji od:
A functional filler comprising: 
osiguravanju funkcionalnog punila, koje sadrži:
A conjugate according to claims 12 to 14 wherein the cell binding agent is chosen from monoclonal antibodies; single chain antibodies; Fab, Fab', F(ab')2 and Fv, interferons; peptides; IL-2, IL-3, IL-4, IL-6; insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, androgens, estrogens; EGF, TGFa, insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF, GM-CSF; folate, transferrin. A pharmaceutical composition comprising a conjugate as defined in claims 12 to 15 or a compound as defined in claims 1 to 11 together with a pharmaceutically acceptable carrier. 
Konjugat u skladu s patentnim zahtjevom 3 do 8, naznačen time što se navedeno sredstvo za vezanje na stanicu bira između monoklonskih protutijela; kimernih protutijela; humaniziranih protutijela; posve ljudskih protutijela; jednolančanih protutijela; fragmenata protutijela, poput Fab, Fab′, F(ab′)2 i Fv, interferona; peptida; limfokina, poput IL-2, IL-3, IL-4, IL-6; hormona, poput inzulina, TRH (tireooslobađajućih hormona), MSH (melanostimulirajućeg hormona), steroidnih hormona, poput androgena i estrogena; čimbenika rasta i čimbenika stimulacije kolonija, poput EGF, TGFa, inzulinu sličnog čimbenika rasta (IGF-I, IGF-II) G-CSF, M-CSF i GM-CSF; vitamina, poput folata i transferina.
A conjugate according to claim 3 wherein said linking group is a thiol, sulfide or disulfide group. 
Konjugat u skladu s patentnim zahtjevom 3, naznačen time što je navedena povezujuća skupina tiolna, sulfidna ili disulfidna skupina.
A conjugate according to claim 3 to 7 wherein said cell binding agent is chosen from antibodies or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules or any other cell binding molecule or substance. 
Konjugat u skladu s patentnim zahtjevom 3 do 7 naznačen time što se navedeno sredstvo za vezanje na stanicu bira između protutijela ili fragmenta protutijela koji sadrži najmanje jedno vežuće mjesto, limfokina, hormona, čimbenika rasta, molekula za prijenos nutrijenata ili bilo koje druge molekule ili tvari koja se veže na stanicu.
A conjugate according to claim 3 to 8, wherein said cell binding agent is chosen from monoclonal antibodies; chimeric antibodies; humanized antibodies; fully human antibodies; single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab')2 and Fv, interferons; peptides; lymphokines such as IL-2, IL-3, IL-4, IL-6; hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens; growth factors and colony-stimulating factors such as EGF, TGFa, insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF; vitamins, such as folate and transferrin. 
Konjugat u skladu s patentnim zahtjevom 3 do 8, naznačen time što se navedeno sredstvo za vezanje na stanicu bira između monoklonskih protutijela; kimernih protutijela; humaniziranih protutijela; posve ljudskih protutijela; jednolančanih protutijela; fragmenata protutijela, poput Fab, Fab′, F(ab′)2 i Fv, interferona; peptida; limfokina, poput IL-2, IL-3, IL-4, IL-6; hormona, poput inzulina, TRH (tireooslobađajućih hormona), MSH (melanostimulirajućeg hormona), steroidnih hormona, poput androgena i estrogena; čimbenika rasta i čimbenika stimulacije kolonija, poput EGF, TGFa, inzulinu sličnog čimbenika rasta (IGF-I, IGF-II) G-CSF, M-CSF i GM-CSF; vitamina, poput folata i transferina.
Process of preparation of a conjugate according to anyone of claims 3 to 9 comprising the step where a compound as defined in claim 1 which comprises a sulfide, disulfide or thiol group, or a precursor thereof, is reacted with a cell binding agent comprising a function reactive towards disulfide or thiol so that the compound and the cell binding agent are linked together via a sulphide or disulfide bond. 
Postupak dobivanja konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što uključuje korak u kojem spoj u skladu s patentnim zahtjevom 1 koji sadrži sulfidnu, disulfidnu ili tiolnu skupinu, ili njegov preteča, reagira sa sredstvom za vezanje na stanicu, koje sadrži funkcionalnu skupinu reaktivnu prema disulfidu ili tiolu, tako da se spoj i sredstvo za vezanje na stanicu poveže zajedno preko sulfidne ili disulfidne veze.
A CD20-specific binding protein for use in treating a B-cell cancer or an autoimmune disease characterized in that the CD20-specific binding protein is to be used in combination with a humanized CD37-specific binding protein for use in treating a B-cell cancer or an autoimmune disease, wherein the humanized CD37-specific binding protein comprises: human light chain framework regions, a light chain CDR1 comprising an amino acid sequence of SEQ ID NO:61, a light chain CDR2 comprising an amino acid sequence of SEQ ID NO:64, and a light chain CDR3 comprising an amino acid sequence of SEQ ID NO:66; and human heavy chain framework regions, a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO:63, a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO:65, and a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 67 or 68. 
Protein koji se specifično veže na CD20 za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti naznačen time što se protein koji se specifično veže na CD20 koristi u kombinaciji s humaniziranim proteinom koji se specifično veže na CD37 za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti, pri čemu humanizirani protein koji se specifično veže na CD37 sadrži: humane okvirne regije lakog lanca, laki lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:61, laki lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:64 i laki lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO:66, i humane okvirne regije teškog lanca, teški lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:63, teški lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:65 i teški lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO: 67 ili 68.
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of claim 14, wherein the immunoglobulin hinge region polypeptide can be an IgG1, IgGA or IgE hinge region polypeptide or a mutant IgG1. 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u patentnom zahtjevu 14, pri čemu polipeptid zglobne regije imunoglobulina može biti IgG1, IgGA ili IgE polipeptid zglobne regije ili mutant IgG1.
the light chain variable region is attached to the heavy chain variable region by a linker peptide comprising (Gly4SER)n, wherein n is 1, 2, 3, 4, 5, or 6; and the linked light and heavy chain variable regions are connected to an IgG1 effector domain via a hinge comprised of an amino acid sequence selected from the group consisting of SEQ ID NO:90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 115, 116, 118, 120, 122, 124, 126, or 127. 
je varijabilna regija lakog lanca povezana na varijabilnu regiju teškog lanca pomoću povezujućeg peptida koji sadrži (Gly4SER)n, pri čemu je n 1, 2, 3, 4, 5 ili 6, i su povezane varijabilne regije lakog i teškog lanca spojene na domenu IgG1 efektora putem zgloba koji se sastoji od aminokiselinskog slijeda odabranog iz skupine koja se sastoji od SEQ ID NO:90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 115, 116, 118, 120, 122, 124, 126, ili 127.
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of any one of the preceding claims, wherein the humanized CD37-specific binding protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 48 and 52. 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u bilo kojem od prethodnih patentnih zahtjeva, pri čemu humanizirani protein koji se specifično veže na CD37 sadrži slijed aminokiseline odabran iz skupine koja se sastoji od SEQ ID NO: 48 i 52.
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of any one of claims 1 to 16, wherein the autoimmune disease is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, Grave's disease, type I diabetes mellitus, psoriasis, immune thrombocytopenic purpura, pemphigus, idiopathic inflammatory myopathy, myasthenis gravis, or Waldenstorm's macroglobinemia. 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u bilo kojem od patentnih zahtjeva 1 do 16, pri čemu je autoimuna bolest reumatoidni artritis, multipla skleroza, sustavni eritematozni lupus, Crohnova bolest, Sjogrenov sindrom, Graveova bolest, dijabetes melitus tipa I, psorijaza, idiopatska trombocitopenična purpura, pemfigus, idiopatska upalna miopatija, mijastenija gravis ili Waldernstormova makroglobulinemija.
Cannabidiol (CBD) for use in the treatment of partial seizure wherein the CBD is present in an amount which provides a daily dose of at least 400mg. 
Kanabidiol (CBD) za primjenu u liječenju parcijalnih napadaja naznačen time da je CBD prisutan u količini koja osigurava dnevnu dozu od najmanje 400mg.
CBD for use in the treatment of partial seizure as claimed in claim 1 wherein the CBD is present in an amount which provides a daily dose of from 400 to 800mg. 
CBD za primjenu u liječenju parcijalnih napadaja prema zahtjevu 1 naznačen time da je CBD prisutan u količini koja osigurava dnevnu dozu od 400 do 800mg.
CBD for use in the treatment of partial seizure as claimed in claim 5, wherein the THCV is present in an amount which provides a daily dose of at least 15 mg. 
CBD za primjenu u liječenju parcijalnih napadaja prema zahtjevu 5, naznačen time da je THCV prisutan u količini koja osigurava dnevnu dozu od najmanje 15 mg.
reacting Compound 3 with a first aqueous base followed by neutralizing to obtain a primary SNS-595 hydrate; 
reakciju spoja 3 [image] sa prvom vodenom bazom, nakon čega slijedi neutraliziranje da se dobije primarni SNS-595 hidrat;
dehydrating the primary SNS-595 hydrate from step (a) and reacting the dehydrated product with a second aqueous base followed by neutralizing to obtain a secondary SNS-595 hydrate; and 
dehidriranje primarnog SNS-595 hidrata iz koraka (a) i reakciju isušenog produkta s drugom vodenom bazom, nakon čega slijedi neutraliziranje da se dobije sekundarni SNS-595 hidrat; i
The process of claim 1, wherein Compound 3 is obtained by reaction of Compound 1 with Compound 2 
Postupak prema zahtjevu 1, naznačen time, da se Spoj 3 dobiva reakcijom spoja 1 [image] sa spojem 2 [image]
reacting Compound 3 with a first aqueous base followed by neutralizing to obtain a primary SNS-595 hydrate; 
reakciju Spoja 3 sa prvom vodenom bazom, nakon čega slijedi neutraliziranje da se dobije primarni SNS-595 hidrat;
reacting the SNS-595 substance from step (c) with a second aqueous base followed by neutralizing to obtain a secondary SNS-595 hydrate; and 
reakciju SNS-595 tvari iz stupnja (c) s drugom vodenom bazom, nakon čega slijedi neutraliziranje da se dobije sekundarni SNS-595 hidrat; i
Composed element according to claim 1, characterized in that the tongue (13) and groove (14) as well as the locking elements are made in one piece as profiled parts in the board material. 
Složeni element u skladu s patentnim zahtjevom 1, karakteriziran na način da su jezičak (13) i žlijeb (14) kao i elementi zaključavanja načinjeni u jednom komadu kao profilirani dijelovi u materijalu ploče.
that it is split; 
da je podijeljen;
Composed element according to any of the preceding claims, characterized in that the corner connection forms an inner and an outer corner and that the tongue (13) and groove (14), globally seen, are situated closer to the inner corner than to the outer corner. 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da kutni spoj oblikuje unutarnji i vanjski kut i da su jezičak (13) i žlijeb (14) smješteni bliže unutarnjem kutu nego vanjskom kutu.
Composed element according to any of the preceding claims, characterized in that said board material relates to particle board with a thickness of 12 to 30 mm. 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da se navedeni materijal ploče odnosi na ploču iverice debljine od 12 do 30 mm.
A bone targeted alkaline phosphatase comprising a polypeptide having the structure: 
Alkalna fosfataza usmjerena na kosti koja sadrži polipeptid koji ima slijedeću strukturu:
X is absent or is an amino acid sequence of at least one amino acid; 
X je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
Y is absent or is an amino acid sequence of at least one amino acid; 
Y je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
Reacting compound A of the following general formula A* wherein 
reakcija tvari A sljedeće opće formule A* [image] pri čemu
represents a leaving group under basic conditions in order to directly obtain (4-pyridin-2-ylphenyl)acetic acid which is then purified. 
predstavlja grupu koja se otcjepljuje pod osnovnim uvjetima zbog izravnog dobivanja (4-piridin-2-ilfenil) octene kiseline koja se nadalje pročišćava.
Method according to claim 1, wherein for the preparation of the intermediate boronic acid derivative or borolane reagent, the reagents palladium acetate, triethylamine and triphenylphosphine or PdCl2(PPh3)2 and triethylamine are used. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu se za pripremu intermedijernog derivata bronične kiseline ili reagensa borolana koriste reagensi paladij acetat, trietilamin i trifenilfosfin, ili PdClj(PPhj)2 i trietilamin.
A process for the preparation of a metal chelated compound or a salt thereof, comprising the steps of: 
Postupak za pripremu metalom kelirane tvari ili njene soli, obuhvaća korake:
A process according to claim 1-3 wherein the metal ion is gadolinium (III). 
Postupak u skladu s patentnim zahtjevom 1 pri čemu je metalni ion gadolinij (III).
A process according to claim 7 wherein the liquid composition is WFI. 
Postupak u skladu s patentnim zahtjevom 7 pri čemu je tekući sastav voda za injekcije.
The process according to any one of claims 1 or 2, wherein said ion solid support is a cation exchange solid support. 
Postupak u skladu s bilo kjim od patentnih zahtjeva 1 ili 2, pri čemu je ionska čvrsta potpora čvrsta potpora kationskog izmjenjivača.
The process according to claim 3, wherein the solid support is a resin derivatized with iminodiacetic acid or thiourea functionalities. 
Postupak u skladu s patentnim zahtjevom 3, pri čemu je čvrsta potpora smola derivatizirana funkcionalnostima iminodioctene kiseline ili tioureje.
The process according to claim 1 wherein the metal ion is gadolinium (III). 
Postupak u skladu s patentnim zahtjevom 1 pri čemu je metalni ion gadolinij (III).
The process according to any one of claims from 1 to 6 wherein the liquid composition in step a) and in step b) is an aqueous solution. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6 pri čemu je tekući sastav u koraku a) i u koraku b) vodena otopina.
The process according to claim 7 wherein the liquid composition is water for injection. 
Postupak u skladu s patentnim zahtjevom 7 pri čemu je tekući sastav voda za injekcije.
A compound represented by the structure of formula VI: wherein R1', R3', R4', R6' R7', and R9' are the same and selected from heterocycloalkyl, alkoxy and dialkylamino, and R10 is methyl; 
Spoj predstavljen strukturnom formulom V: [image] u kojoj je R7 metil grupa, a R1', R2', R3', R4' R5', i R6' iste ili različite grupe izabrane od dialkilamino, N-piperidin, N-pirolidin, N-piperazin, N-piperazine-4-metil i N-morfolin.
A compound or salt according to any one of claims 1 to 4, wherein R3 is a C1 to C6 alkyl group, a benzyl group, or an indolylmethyl group (the indolyl group optionally being substituted at the nitrogen atom thereof by a C1 to C6 alkyl group). 
Spoj ili sol prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je R3 C1 do C6 alkilna skupina, benzilna skupina, ili indolilmetilna skupina (indolilna skupina po izboru je supstituirana na dušikovom atomu s C1 do C6 alkilnom skupinom).
Device according to any of the previous claims, wherein the proximal articulation arm (16) comprises a pair of longitudinal sections (22, 24), staggered from each other, joined by a connection loop (26). 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time, da bliža ustrojna ručica (16) obuhvaća par uzdužnih elemenata (22, 24) nepravilno međusobno raspoređenih i spojenih veznom omčom (26).
Storage furniture unit (6), preferably a storage bed or sofa-bed, comprising: 
Cjelina za uklapanje namještaja (6) poželjno krevet na sklapanje ili sofa na sklapanje, naznačena time, da obuhvaća:
a mattress support (2), joined to the furniture frame (4) and having a support surface (8) positioned on a base plane (X); 
nosač madraca (2), spojen na okvir namještaja (4), koji ima nosivu površinu (8) položenu na baznu ravninu (X);
Storage furniture unit according to claim 14, wherein the furniture frame (4) defines a storage compartment (34) which, in the rest configuration, houses the device for moving (1). 
Cjelina za uklapanje namještaja prema zahtjevu 14, naznačena time, da okvir namještaja (4) određuje spremišni odjeljak (34) koji u položenom postavu smještava uređaj za pomicanje (1).
A pharmaceutical composition according to claim 1, wherein the compound of formula (1) is present as the sodium salt. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je spoj formule (1) prisutan kao natrijeva sol.
A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable lipid is selected from: fatty acids, medium or long chain mono-, di- or triglycerides, propylene glycol fatty acid esters, sorbitol fatty acid esters, water insoluble vitamins, and mixtures thereof. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je farmaceutski prihvatljiv lipid odabran od sljedećih: masne kiseline, mono-, di- ili trigliceridi srednjeg ili dugog lanca, esteri masnih kiselina propilen glikola, esteri masnih kiselina sorbitola, vitamini netopivi u vodi i njihove mješavine.
A pharmaceutical composition according to any of the preceding claims, wherein the pharmaceutically acceptable hydrophilic surfactant is selected from polyethoxylated vegetable oils, polyethoxylated tocopherols, polyethoxylated sorbitol fatty acid esters, bile salts, lecithins and mixtures thereof. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je farmaceutski prihvatljiv hidrofilni tenzid odabran od sljedećih: polietoksilirana biljna ulja, polietoksilirani tokoferoli, polietoksilirani esteri masne kiseline sorbitola, žučne soli, lecitini, te njihove mješavine.
A pharmaceutical composition according to claim 8, wherein the pharmaceutically acceptable hydrophilic solvent is selected from propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water, or mixtures thereof. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je farmaceutski prihvatljivo hidrofilno otapalo odabrano od sljedećih: propilen glikol, polipropilen glikol, polietilen glikol, glicerin, etanol, dimetil izosorbid, glikofurol, propilen karbonat, dimetil acetamid, voda, ili njihove mješavine.
A pharmaceutical composition according to claims 8 or 9, wherein the pharmaceutically acceptable hydrophilic solvent is present in an amount of up to 30% by weight. 
Farmaceutski sastav prema zahtjevu 8 ili 9, naznačen time, da je farmaceutski prihvatljivo hidrofilno otapalo prisutno u količini do 30 masenih %.
A pharmaceutical composition according to any of the preceding claims, wherein upon dilution with an aqueous solution at an aqueous solution to composition ratio of 100: 1 by weight, the composition forms an aqueous dispersion having an absorbance of more than 1.0 at a wavelength of 400 nm. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nakon razgradnje s vodenom otopinom, u omjeru vodene otopine prema farmaceutskom sastavu od 100:1 po masi, sastav stvara vodenu disperziju koja ima upijanje veće od 1,0 na valnoj duljini od 400 nm.
30% to 60% by weight of a pharmaceutically acceptable lipid selected from fatty acids, medium or long chain mono-, di- or triglycerides, propylene glycol fatty acid esters, sorbitol fatty acid esters, water insoluble vitamins, and mixtures thereof; 
do 60 masenih % farmaceutski prihvatljivog lipida odabranog od masnih kiselina, mono-, di- ili triglicerida srednjeg ili dugog lanca, estera masnih kiselina propilen glikola, estera masnih kiselina sorbitola, vitamina netopivih u vodi, te njihovih mješavina;
optionally up to 30%) by weight of a pharmaceutically acceptable hydrophilic solvent selected from propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, water, or mixtures thereof; or (D) 
opcijski do 30 masenih % farmaceutski prihvatljivog hidrofilnog otapala odabranog od propilen glikola, polipropilen glikola, polietilen glikola, glicerina, etanola, dimetil izosorbida, glikofurola, propilen karbonata, dimetil acetamida, vode, te njihovih mješavina; ili
25% to 35% by weight of a pharmaceutically acceptable hydrophilic surfactant selected from tocopheryl polyethylene glycol succinate, polyoxyl 40 hydrogenated castor oil, and polyoxyl 35 castor oil and mixtures thereof; 
do 35 masenih % farmaceutski prihvatljivog hidrofilnog tenzida odabranog od tokoferil polietilen glikol sukcinata, polioksil 40 hidrogeniziranog ricinusovog ulja i polioksil 35 ricinusovog ulja, te njihovih mješavina;
The use as claimed in claim 6, wherein the crops are crops of wheat, barley, rye, triticale, durum, rice, corn, sugarcane, sorghum, soybean, pulse crops, peanut, sunflower, sugarbeet, potato, cotton, brassica crops, turf, grapes, pomefruit, stonefruit, citrus, coffee, pistachio, garden ornamentals, bulb ornamentals, conifers and deciduous trees. 
Primjena u skladu sa zahtjevom 6, naznačena time što su usjevske biljke usjevi pšenice, ječma, raži, tritikale pšenice, durum pšenice, riže, kukuruza, šećerne trske, siraka, soje, mahunarki, kikirikija, suncokreta, šećerne repe, krumpira, pamuka, kupusnjača, travnatih terena, grožđa, jabučastih biljaka, koštuničavih biljaka, citrusa, kave, pistacio, vrtnih biljaka, lukovica, četinarskog i listopadnog drveća.
A 3,8-diaminotetrahydroquinoline derivative represented by formula (1 a): 
Derivat 3,8-diaminotetrahidrokinolina, naznačen time, da je to spoj predstavljen formulom (1 a):
A compound represented by formula (F1): 
Spoj naznačen time, da je to spoj predstavljen formulom (F1):